Clinical and Molecular Studies in Families With Inherited Eye Disease
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02771236 |
|
Recruitment Status :
Recruiting
First Posted : May 13, 2016
Last Update Posted : February 16, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background:
Genes are the basic units of heredity. When genes are changed, certain cells don t work like they should. Researchers want to try to better understand the genetic conditions that are linked with inherited eye diseases.
Objective:
To try to identify the genes linked to the development of inherited eye diseases.
Eligibility:
People ages 4 and older who have or have a family member with an inherited eye disease
Design:
Participants will be screened with medical history and medical records.
Participants will have one visit that will take 3 4 hours. This will include:
Medical and family history
Eye exam: This includes the pupil being dilated.
Electroretinography: A small electrode is taped to the forehead. Participants sit in the
dark with their eyes patched for 30 minutes. Then numbing drops and contact lenses are put in
the eyes. They will watch flashing lights.
Blood tests
Saliva sample: They will spit into a container or have the inside of their cheek swabbed.
Genetic testing will be done on participants blood or saliva.
Participants may meet with the researchers to discuss their genetic tests.
| Condition or disease |
|---|
| Inherited Eye Disease |
Objective: This project, Clinical and Molecular Studies in Families with Inherited Eye Disease will study inherited eye diseases, both Mendelian and complex age related inherited eye diseases, in families of many nationalities and ethnic backgrounds in order to identify the genes that, when mutated, cause inherited eye diseases and the pathophysiology through which they act. Among the diseases studied will be cataracts, corneal dystrophies and other corneal diseases, retinal degenerations, myopia and other anterior chamber defects, and glaucoma.
Study Population: Families and individuals of many nationalities and ethnic backgrounds. We will study a maximum of 5,000 patients and family members.
Design: The study consists of ascertaining individuals and especially families with multiple individuals, affected by both congenital and age related inherited eye diseases. These participants and their families will undergo detailed ophthalmological examinations to characterize their visual system and determine their affectation status. A blood sample will be collected from each individual for isolation of DNA and in some individuals for lymphoblastoid transformation to establish a renewable source of DNA. Linkage analysis, association analysis, physical mapping, and mutational screening will be carried out to identify the specific gene and the mutations in it that are associated with inherited eye disease in the family. Mutation screening may involve Sanger sequencing if a small number of candidate genes are identified, or whole genome or whole exome sequencing if more genes remain as viable candidates after the initial analysis. If necessary, the gene product will be characterized biochemically. Blood samples may also be used to complete analyses such as: hemoglobin A1c (HbA1c), fasting blood glucose, and glucose tolerance tests. The study will enroll participants at NEI and collaborating institutions.
Outcome Measures: Linkage will be determined using the lod score method, association will be determined using standard statistical procedures to estimate p values, and mutations in specific genes will be assessed using a combination of residue conservation, blosum score, bioinformatic prediction of structural damage to the protein, and molecular modeling. Assessment of biochemical, metabolic, and physiological effects of these mutations will be individualized to the specific case.
| Study Type : | Observational |
| Estimated Enrollment : | 5000 participants |
| Observational Model: | Cohort |
| Time Perspective: | Cross-Sectional |
| Official Title: | Clinical and Molecular Studies in Families With Inherited Eye Disease |
| Actual Study Start Date : | October 4, 2016 |
| Estimated Primary Completion Date : | January 1, 2032 |
| Estimated Study Completion Date : | January 1, 2032 |
| Group/Cohort |
|---|
|
Participants with cataracts
Participants with cataracts
|
|
Participants with corneal dystrophies
Participants with corneal dystrophies
|
|
Participants with glaucoma
Participants with glaucoma or other anterior chamber anomalies
|
|
Participants with lens refractive errors
Participants with lens refractive errors including myopia and hyperopia
|
|
Participants with retinal degenerations
Participants with retinal degenerations
|
- Document the clinical and genetic features of Mendelian and age related visual disorders [ Time Frame: Study duration ]Provide improved diagnosis and categorization of inherited visual disorders and should eventually suggest rationales for prevention or delay of both Mendelian and complex eye diseases
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 4 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
- INCLUSION CRITERIA:
To be eligible, the following inclusion criteria must be met, where applicable;
- Participant must be four years of age or older.
- Participant must understand and sign the protocol s informed consent document.
- Individuals or family members of individuals with inherited eye diseases, either congenital, childhood, or age related.
- All participants must be able to cooperate with study examination and phlebotomy.
EXCLUSION CRITERIA:
A participant is not eligible if any of the following exclusion criteria are present:
- Participant has a disease, infection, or trauma that mimic inherited cataracts, retinal degenerations, glaucoma, etc.
- Participant has a significant active infection (an infection requiring treatment as determined by the investigator) or a history of chronic or recurrent infections.
- Participant requires sedation for study procedures.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02771236
| Contact: James F Hejtmancik, M.D. | (301) 435-1598 | f3h@helix.nih.gov |
| United States, California | |
| University of California, San Diego | Recruiting |
| La Jolla, California, United States, 92093-0603 | |
| Contact: Radha Ayyagari, Ph.D. 858-534-9029 rayyagari@ucsd.edu | |
| United States, Maryland | |
| National Institutes of Health Clinical Center | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov | |
| China | |
| Eye Research Institute, Zhongshan Ophthalmic Center, Sun Yat Sen University | Recruiting |
| Guangzhou, China | |
| Pakistan | |
| National Centre of Excellence in Molecular Biology, University of the Punjab | Recruiting |
| Lahore, Pakistan, 53700 | |
| Philippines | |
| University of the Philippines | Recruiting |
| Manila, Philippines, 4031 | |
| Contact: Leo Cubillan, M.D. 63-2-5247119 lcubillan@upm.edu.ph | |
| Ukraine | |
| The Filatov Institute of Eye Disease and Tissue Therapy of the National Academy | Recruiting |
| Odesa, Ukraine, 6500 | |
| Principal Investigator: | James F Hejtmancik, M.D. | National Eye Institute (NEI) |
| Responsible Party: | National Eye Institute (NEI) |
| ClinicalTrials.gov Identifier: | NCT02771236 |
| Other Study ID Numbers: |
160104 16-EI-0104 |
| First Posted: | May 13, 2016 Key Record Dates |
| Last Update Posted: | February 16, 2023 |
| Last Verified: | February 13, 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Genetics Natural History |
|
Eye Diseases |